{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:11:11Z","timestamp":1778217071008,"version":"3.51.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore the effect of a nurse-led multidisciplinary team (MDT) model on chemotherapy-induced nausea and vomiting (CINV) in lung cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 126 non-small cell lung cancer patients undergoing platinum-based chemotherapy were divided into a control group (routine care, n=63) and an experimental group (nurse-led MDT intervention, n=63). The primary outcome was the incidence of grade \u2265II CINV. Secondary outcomes included scores on the Functional Living Index-Emesis (FLIE), patient cognition of CINV, and satisfaction with CINV management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The experimental group showed significantly lower frequency and severity of nausea and vomiting at day 5 of chemotherapy cycle 2 (P&amp;lt;0.05). FLIE scores, patient cognition, and satisfaction were all significantly higher in the experimental group (all P&amp;lt;0.001). No severe adverse events were reported during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The nurse-led MDT model effectively reduces the severity of CINV, improves quality of life and patient satisfaction, and enhances the standardized management of CINV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1828714","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:47:40Z","timestamp":1778215660000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of a nurse-led multidisciplinary team model on chemotherapy-induced nausea and vomiting in lung cancer patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Wei","family":"Liu","sequence":"first","affiliation":[{"name":"Clinical Center For Tumer Therapy, The Second Affiliated Hospital of Chongqing Medical University","place":["ChongQing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Peng","sequence":"additional","affiliation":[{"name":"Nursing department, The Second Affiliated Hospital of Chongqing Medical University","place":["ChongQing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuni","family":"Gan","sequence":"additional","affiliation":[{"name":"Nursing department, The Second Affiliated Hospital of Chongqing Medical University","place":["ChongQing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"j.issn.2095-3941.2025.0625","DOI":"10.20892\/j.issn.2095-3941.2025.0625","article-title":"Lung cancer mortality trends in China from 2013 to 2021 and projections to 2030","volume":"20","author":"Liang","year":"2026","journal-title":"Cancer Biol Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00685-3","article-title":"Mitigating acute chemotherapy-associated adverse events in patients with cancer","volume":"19","author":"Kuderer","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115451","article-title":"Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"222","author":"Jordan","year":"2025","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100278","article-title":"Chemotherapy-induced nausea and vomiting: Pathogenesis, recommendations, and new trends","volume":"26","author":"Gupta","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2530","article-title":"Changes in antiemetic overuse in response to Choosing Wisely recommendations","volume":"3","author":"Encinosa","year":"2017","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/curroncol32060325","article-title":"Incidence and risk factors of platinum-based chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis","volume":"32","author":"Jin","year":"2025","journal-title":"Curr Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4741193","article-title":"Evidence summary for nonpharmacological management of chemotherapy-induced nausea and vomiting","volume":"2022","author":"Li","year":"2022","journal-title":"BioMed Res Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S566098","article-title":"Multidisciplinary team (MDT)-based approaches for liver cancer treatment: A discussion paper on tumor boards and beyond","volume":"18","author":"Qi","year":"2025","journal-title":"J Multidiscip Healthc"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e30965","article-title":"Electrical acupoint stimulation for the treatment of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis","volume":"10","author":"Ying","year":"2024","journal-title":"Heliyon"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2025.105094","article-title":"Risk prediction model for chemotherapy-induced nausea and vomiting in cancer patients: A systematic review","volume":"168","author":"Wang","year":"2025","journal-title":"Int J Nurs Stud"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1726136","article-title":"Chemotherapy-induced nausea and vomiting (CINV) with GI cancer chemotherapy: Do we need CINV risk score over and above antiemetic guidelines in prescribing antiemetic regime","volume":"9","author":"D'Souza","year":"2021","journal-title":"South Asian J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185254","article-title":"ShenQi FuZheng injection combined with chemotherapy in the treatment of colorectal cancer: A meta-analysis","volume":"12","author":"Xu","year":"2017","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1007\/s12094-022-02846-3","article-title":"Correction to: SEOM clinical guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021)","volume":"24","author":"Majem","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol33010027","article-title":"Olanzapine plus triple antiemetic therapy for the prevention of platinum-based delayed-phase chemotherapy-induced nausea and vomiting: A meta-analysis","volume":"33","author":"Gong","year":"2026","journal-title":"Curr Oncol"},{"key":"B16","article-title":"Comprehensive integrative oncology","author":"Loy","year":"2026"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6494","article-title":"Influence of menopause on chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study","volume":"12","author":"Yokokawa","year":"2023","journal-title":"Cancer Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: Results from a European prospective observational study","volume":"47","author":"Molassiotis","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/nop2.70490","article-title":"Incidence and risk factors of delayed chemotherapy-induced nausea and vomiting among adult patients: A cross-sectional study","volume":"13","author":"Zheng","year":"2026","journal-title":"Nurs Open"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00329","article-title":"Patient-related risk factors for chemotherapy-induced nausea and vomiting: A systematic review","volume":"11","author":"Mosa","year":"2020","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1828714\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:47:46Z","timestamp":1778215666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1828714\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":20,"alternative-id":["10.3389\/fonc.2026.1828714"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1828714","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1828714"}}